2004
DOI: 10.1097/00075197-200409000-00009
|View full text |Cite
|
Sign up to set email alerts
|

The butyrate story: old wine in new bottles?

Abstract: In the era of molecular biology our understanding of subcellular processes that ultimately lead to inflammatory bowel disease or colorectal cancer has widened considerably. The new powerful technology of genomics and proteomics, however, raises new questions without easy answers. With this new information in mind, we will have to go back to human intervention trials to test the hypotheses generated in vitro. The preclinical data from the review period justify the need for carefully designed clinical trials to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
158
0
4

Year Published

2007
2007
2018
2018

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 233 publications
(165 citation statements)
references
References 26 publications
1
158
0
4
Order By: Relevance
“…The application of SCFAs in the excluded colon was experimentally demonstrated to improve the inflammatory process, while the interrupted application promoted the disease dissemination 10 . The deficient supply of SCFAs as a factor that triggers DC was confirmed with the results of clinical and experimental studies showing that the restoration of fecal stream or the application of butyrate-rich solutions, the main subtype of SCFAs metabolized by colonocytes, reverted the clinical symptoms and the characteristic endoscopic and histological alterations of the disease [11][12][13][14][15][16][17][18][19] . However, despite these evidences, the molecular mechanisms through which the deficient supply of SCFAs determines the tissue inflammation, have not been fully explained 20 .…”
Section: Introductionmentioning
confidence: 81%
“…The application of SCFAs in the excluded colon was experimentally demonstrated to improve the inflammatory process, while the interrupted application promoted the disease dissemination 10 . The deficient supply of SCFAs as a factor that triggers DC was confirmed with the results of clinical and experimental studies showing that the restoration of fecal stream or the application of butyrate-rich solutions, the main subtype of SCFAs metabolized by colonocytes, reverted the clinical symptoms and the characteristic endoscopic and histological alterations of the disease [11][12][13][14][15][16][17][18][19] . However, despite these evidences, the molecular mechanisms through which the deficient supply of SCFAs determines the tissue inflammation, have not been fully explained 20 .…”
Section: Introductionmentioning
confidence: 81%
“…Xylanibacter, Prevotella, Butyrivibrio, and Treponema are exclusive to the BF children ( Fig. S2) and indicate the presence of a bacterial community using xylane, xylose, and carboxymethylcellulose to produce high levels of SCFAs (18) whose protective role against gut inflammation has been well proven (19). These bacteria can ferment both xylan and cellulose through carbohydrate-active enzymes such as xylanase, carboxymethylcellulase, and endoglucanase (http://www.cazy.org).…”
Section: Dominance Of the Bacteroidetes In Gut Microbiota Of Burkina mentioning
confidence: 99%
“…For example, the concentration of butyrate in the colon can reach millimolar concentrations, as a consequence of bacterial fermentation of carbohydrate. 70 Thus, one function of HP1 proteins might be to protect cells from the detrimental effects of such toxins.…”
Section: The Cellular Role Of Hp1 Proteinsmentioning
confidence: 99%